Gabriele Bergers

List of Publications by Year
in descending order

63 papers	25,513 citations	53751 45 h-index	133188 59 g-index
64 all docs	64 docs citations	64 times ranked	28656 citing authors

#	Article	IF	Citations
1	LGL1 binds to Integrin Î²1 and inhibits downstream signaling to promote epithelial branching in the mammary gland. Cell Reports, 2022, 38, 110375.	2.9	6
2	Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nature Communications, 2022, 13, 2760.	5.8	19
3	The metabolism of cancer cells during metastasis. Nature Reviews Cancer, 2021, 21, 162-180.	12.8	431
4	High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. Frontiers in Immunology, 2021, 12, 736670.	2.2	26
5	Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release, 2019, 308, 109-118.	4.8	60
6	Tumors vs. Chronic Wounds: An Immune Cell's Perspective. Frontiers in Immunology, 2019, 10, 2178.	2.2	52
7	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. Annual Review of Physiology, 2019, 81, 535-560.	5.6	44
8	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. Journal of Pathology, 2018, 245, 209-221.	2.1	70
9	Where Have All the T Cells Gone?. Immunity, 2018, 49, 592-594.	6.6	4
10	A tension-mediated glycocalyxâ€"integrin feedback loop promotes mesenchymal-like glioblastoma. Nature Cell Biology, 2018, 20, 1203-1214.	4.6	103
11	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	3.7	429
12	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Seminars in Cancer Biology, 2018, 52, 107-116.	4.3	57
13	Combined antiangiogenic and antiâ€"PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine, 2017, 9, .	5.8	541
14	Cross-activating c-Met/Î²1 integrin complex drives metastasis and invasive resistance in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8685-E8694.	3.3	60
15	Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. Oncotarget, 2017, 8, 99207-99208.	0.8	9
16	Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 21-29.	2.0	5
17	Glioblastoma: Defining Tumor Niches. Trends in Cancer, 2015, 1, 252-265.	3.8	326
18	Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy. Cell Reports, 2015, 11, 577-591.	2.9	136

#	Article	IF	Citations
19	Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends in Immunology, 2015, 36, 240-249.	2.9	122
20	Tumor angiogenesis, from foe to friend. Science, 2015, 349, 694-695.	6.0	104
21	HRâ€MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR in Biomedicine, 2014, 27, 1361-1370.	1.6	24
22	Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors. Molecular Cancer Therapeutics, 2014, 13, 996-1007.	1.9	54
23	Targeting vascular sprouts. Science, 2014, 344, 1449-1450.	6.0	23
24	Escape Mechanisms from Antiangiogenic Therapy: An Immune Cellâ€™s Perspective. Advances in Experimental Medicine and Biology, 2014, 772, 83-99.	0.8	11
25	Location, Location, Location: Macrophage Positioning within Tumors Determines Pro- or Antitumor Activity. Cancer Cell, 2013, 24, 687-689.	7.7	43
26	Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncology, 2013, 2, 49-65.	1.2	116
27	Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. Clinical Cancer Research, 2013, 19, 1773-1783.	3.2	177
28	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. Cancer Cell, 2012, 22, 21-35.	7.7	495
29	Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors. Cancer Cell, 2011, 20, 328-340.	7.7	200
30	Tumor microenvironment and progression. Journal of Surgical Oncology, 2011, 103, 468-474.	0.8	149
31	Non-Stem Cell Origin for Oligodendroglioma. Cancer Cell, 2010, 18, 669-682.	7.7	211
32	Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Research, 2009, 69, 6889-6898.	0.4	136
33	Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell, 2009, 15, 220-231.	7.7	2,168
34	Bone Marrow-Derived Cells in GBM Neovascularization. , 2009, , 749-773.		4
35	Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 2008, 8, 592-603.	12.8	2,603
36	miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Medicine, 2008, 6, 14.	2.3	819

#	Article	IF	Citations
37	HIF1Î± Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion. Cancer Cell, 2008, 13, 206-220.	7.7	1,037
38	Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro-Oncology, 2008, 10, 254-264.	0.6	94
39	Chapter 3 Bone Marrowâ€"Derived Vascular Progenitors and Proangiogenic Monocytes in Tumors. Methods in Enzymology, 2008, 445, 53-82.	0.4	3
40	Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting. PLoS Medicine, 2008, 5, e19.	3.9	383
41	Pericytes, the Mural Cells of the Microvascular System. , 2008, , 45-53.		3
42	HIFÎ± induces the recruitment of bone marrowâ€derived vascular modulatory cells to regulate tumor angiogenesis. FASEB Journal, 2008, 22, 88.2.	0.2	0
43	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. Cancer Research, 2007, 67, 9435-9442.	0.4	58
44	Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer and Metastasis Reviews, 2006, 25, 243-252.	2.7	26
45	The PTEN/Akt Pathway Dictates the Direct Î±VÎ²3-Dependent Growth-Inhibitory Action of an Active Fragment of Tumstatin in Glioma Cells In vitro and In vivo. Cancer Research, 2006, 66, 11331-11340.	0.4	57
46	The bone marrow constitutes a reservoir of pericyte progenitors. Journal of Leukocyte Biology, 2006, 80, 677-681.	1.5	119
47	Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood, 2005, 105, 1094-1101.	0.6	181
48	PDGFRÎ²+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biology, 2005, 7, 870-879.	4.6	518
49	Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8, 299-309.	7.7	1,478
50	The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology, 2005, 7, 452-464.	0.6	1,252
51	Integrin Î²3 Overexpression Suppresses Tumor Growth in a Human Model of Gliomagenesis. Cancer Research, 2004, 64, 2751-2758.	0.4	55
52	The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003, 4, 133-146.	7.7	375
53	Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2003, 4, 393-403.	7.7	232
54	Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 2003, 3, 401-410.	12.8	3,059

#	Article	IF	Citations
55	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 2003, 111, 1287-1295.	3.9	560
56	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 2003, 111, 1287-1295.	3.9	1,107
57	Cell factories for fighting cancer. Nature Biotechnology, 2001, 19, 20-21.	9.4	10
58	Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation, 2000, 105, 1045-1047.	3.9	704
59	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2000, 2, 737-744.	4.6	2,487
60	Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Expert Opinion on Therapeutic Targets, 2000, 4, 609-633.	1.0	67
61	Extrinsic regulators of epithelial tumor progression: metalloproteinases. Current Opinion in Genetics and Development, 2000, 10, 120-127.	1.5	140
62	MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes. Cell, 1998, 93, 411-422.	13.5	1,639
63	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340.		31